Franklin Resources’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.55M | Buy |
312,628
+3,566
| +1% | +$80.3K | ﹤0.01% | 1412 |
|
|
2025
Q4 | $7.11M | Sell |
309,062
-368,122
| -54% | -$12.1M | ﹤0.01% | 1273 |
|
|
2025
Q3 | $20.4M | Buy |
677,184
+202,028
| +43% | +$6.06M | 0.01% | 948 |
|
|
2025
Q2 | $17.3M | Sell |
475,156
-125,290
| -21% | -$4.52M | ﹤0.01% | 969 |
|
|
2025
Q1 | $21.7M | Buy |
600,446
+173,087
| +41% | +$7.2M | 0.01% | 880 |
|
|
2024
Q4 | $18M | Buy |
427,359
+208,456
| +95% | +$10.3M | 0.01% | 940 |
|
|
2024
Q3 | $12.3M | Sell |
218,903
-74,991
| -26% | -$3.82M | ﹤0.01% | 1048 |
|
|
2024
Q2 | $12.1M | Buy |
293,894
+77,978
| +36% | +$3.33M | ﹤0.01% | 1012 |
|
|
2024
Q1 | $10.1M | Buy |
215,916
+1,178
| +0.5% | +$55.6K | ﹤0.01% | 1073 |
|
|
2023
Q4 | $10.3M | Buy |
214,738
+25,144
| +13% | +$975K | ﹤0.01% | 925 |
|
|
2023
Q3 | $6.76M | Buy |
189,594
+9,976
| +6% | +$395K | ﹤0.01% | 1002 |
|
|
2023
Q2 | $8.29M | Buy |
179,618
+126
| +0.1% | +$5.84K | ﹤0.01% | 969 |
|
|
2023
Q1 | $7.2M | Sell |
179,492
-1,600
| -0.9% | -$68.7K | ﹤0.01% | 1003 |
|
|
2022
Q4 | $8.39M | Buy |
181,092
+2,729
| +2% | +$107K | ﹤0.01% | 980 |
|
|
2022
Q3 | $7.39M | Sell |
178,363
-834
| -0.5% | -$42.9K | ﹤0.01% | 1009 |
|
|
2022
Q2 | $10.7M | Hold |
179,197
| – | – | 0.01% | 940 |
|
|
2022
Q1 | $13M | Sell |
179,197
-14
| -0% | -$974 | 0.01% | 952 |
|
|
2021
Q4 | $15.1M | Sell |
179,211
-23,250
| -11% | -$1.89M | 0.01% | 963 |
|
|
2021
Q3 | $18.3M | Buy |
202,461
+76
| +0% | +$6.87K | 0.01% | 913 |
|
|
2021
Q2 | $19.3M | Sell |
202,385
-42
| -0% | -$4.38K | 0.01% | 867 |
|
|
2021
Q1 | $23M | Sell |
202,427
-51,651
| -20% | -$7.03M | 0.01% | 807 |
|
|
2020
Q4 | $35.2M | Sell |
254,078
-128,749
| -34% | -$15.3M | 0.01% | 684 |
|
|
2020
Q3 | $31.5M | Buy |
382,827
+354
| +0.1% | +$29.3K | 0.02% | 666 |
|
|
2020
Q2 | $31.7M | Hold |
382,473
| – | – | 0.02% | 633 |
|
|
2020
Q1 | $17M | Buy |
382,473
+11,823
| +3% | +$614K | 0.01% | 707 |
|
|
2019
Q4 | $15.8M | Buy |
370,650
+225,200
| +155% | +$9.29M | 0.01% | 811 |
|
|
2019
Q3 | $6.22M | Buy |
+145,450
| New | +$7.9M | ﹤0.01% | 965 |
|
|
2015
Q3 | – | Sell |
-214,300
| Closed | -$21.9M | – | 1619 |
|
|
2015
Q2 | $21.9M | Hold |
214,300
| – | – | 0.01% | 866 |
|
|
2015
Q1 | $13.3M | Hold |
214,300
| – | – | 0.01% | 979 |
|
|
2014
Q4 | $9.4M | Sell |
214,300
-6,500
| -3% | -$298K | ﹤0.01% | 1059 |
|
|
2014
Q3 | $12.5M | Sell |
220,800
-22,300
| -9% | -$1.12M | 0.01% | 1009 |
|
|
2014
Q2 | $10.9M | Hold |
243,100
| – | – | ﹤0.01% | 1043 |
|
|
2014
Q1 | $11.9M | Buy |
+243,100
| New | +$12.5M | 0.01% | 995 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Franklin Resources's RARE Position: Q1 2026 in Review
Franklin Resources increased its Ultragenyx Pharmaceutical (RARE) stake by 1.2% in Q1 2026, buying an estimated $80.3K and bringing the position to 312,628 shares worth $6.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1412.
Franklin Resources first reported a position in RARE in Q1 2014 and has held it in 33 quarters since. The position peaked at $35.2M in Q4 2020. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Franklin Resources held 312,628 shares of Ultragenyx Pharmaceutical worth $6.55M as of Q1 2026.
- Franklin Resources bought 3,566 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $80.3K.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Franklin Resources's portfolio in Q1 2026, its #1412 holding.
- Franklin Resources first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 33 quarters since.
- Franklin Resources's Ultragenyx Pharmaceutical position peaked at $35.2M in Q4 2020.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Franklin Resources's 13F filing for Q1 2026, filed 13 May 2026.